Efficacy of the Priority Review Voucher Program (Reply)

The authors argue that the priority review voucher program is not a sensible way to incentivize tropical disease drug development because it disrupts the FDA’s calibrated review process, risks wasting public funds by accelerating reimbursement of potentially noninnovative drugs by government insurance programs, and is easily gamed. Instead, greater NIH funding should be directed toward translational tropical disease research.